Anti-inflammatory therapy in chronic obstructive pulmonary disease: present and future

Abstract

Today chronic obstructive pulmonary disease is a major economic and social challenge and the only disease causing an ever-increasing number of fatalities [4, 5]. According to a number of recently completed studies, the prevalence of chronic lung diseases in people aged over 40 years is 10.1 per cent (11.8 for men and 8.5 per cent for women) globally (3).

Keywords

• хроническая обструктивная болезнь легких
• т-лымфоциты
• мокрота
• рофлумиласт
• chronic obstructive pulmonary disease
• t-lymphocytes
• sputum
• roflumilast